GW Pharmaceuticals secures official NICE approval for EPIDYOLEX®
Category: #health  By Mateen Dalal  Date: 2019-11-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

GW Pharmaceuticals secures official NICE approval for EPIDYOLEX®

GW Pharmaceuticals plc has reportedly announced that two of its medicines, Sativex (nabiximols) and EPIDYOLEX (cannabidiol) oral solution, have been advised by National Institute for Health and Care Excellence (NICE) of the U.K. to get routine compensation from NHS England.

Apparently, for the first-time any plant-derived cannabis-based drug has been advised by NICE for use on NHS. Cannabidiol oral solution is suggested as an adjunctive treatment for seizures related to Dravet syndrome or Lennox Gastaut syndrome (LGS), in conjunction with clobazam, for patients aged two years and older. In addition, Nabiximols, assessed as part of NICE’s analysis of cannabis-based medicinal products (CBMPs), has been considered economical for treatment of spasticity caused by multiple sclerosis.

Chris Tovey, Chief Operating Officer, GW, reportedly stated that this is a significant event for patients and families in the U.K. who have waited since a very long time for rigorously tested, proved and regulatory approved cannabis-based medication to be reimbursed by NHS. The recommendation by NICE has proved that cannabis-based drugs can effectively go through extensive randomized placebo-controlled tests and a rigorous evaluation process of NICE to reach patients.

Reportedly, cannabidiol oral solution has secured approval based on outcomes from four randomized, controlled Phase III studies. These trials include data from over 714 patients with either Dravet or LGS syndrome. Both the diseases are two rare forms of epilepsy with high mortality and morbidity rates, which considerably burdens caregivers and families. Several patients with Dravet or LGS syndrome go through multiple seizures per day, which increase the ongoing risk of injury and falls. Regardless of current anti-epileptic drug therapy, both of these rare forms of epilepsy have remained as extremely treatment resistant.

According to reliable sources, after the approval, GW has been functioning with the related bodies in Germany, the U.K., Spain, Italy, and France. The company intends to obtain reimbursement before anticipated launch of medication in these nations.
 

Source credits:

http://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-receives-positive-nice-recommendation

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

40% of COVID-19 patients are asymptomatic, a new CDC report claims
40% of COVID-19 patients are asymptomatic, a new CDC report claims
By Mateen Dalal

The ongoing coronavirus pandemic has wreaked havoc worldwide. Dismissed as a slight by the world initially, the virus shocked the scientific and medical communities alike, with the rapid rate of spreading. Very little information about the novel coro...

AI-centric study abroad platform Edvoy launched by IEC Abroad in India
AI-centric study abroad platform Edvoy launched by IEC Abroad in India
By Mateen Dalal

AI oriented study abroad platform, Edvoy, based out of UK, has reportedly declared its launch in India.  Edvoy, created by IEC Abroad, is a free digital platform that provides impartial advice, support, and content to prospective international s...

Centuria announces Augusta Capital takeover offer to be unconditional
Centuria announces Augusta Capital takeover offer to be unconditional
By Mateen Dalal

  Acceptance to takeover represent 65.86% of Augusta’s shares Takeover provide shareholders with NZ$0.22 in cash and 0.392 Centuria stapled securities for every share of Augusta Centuria’s assets under management will increase b...